

1 **Toxicity of Cobalt-Chromium nanoparticles released from a resurfacing hip implant**
2 **and Cobalt ions on primary human lymphocytes *in vitro***

3 Olga M Posada^{1,1}, R. J. Tate², and M. H. Grant¹

4 ¹Biomedical Engineering Department, University of Strathclyde, Wolfson Centre, Glasgow,
5 UK.

6 ²Strathclyde Institute for Pharmacy & Biomedical Sciences, University of Strathclyde,
7 Glasgow, UK. G4 0RE, UK.

8
9 **Running title:** *CoCr nanoparticle toxicity in lymphocytes*

10
11 **Abstract**

12 Adverse tissue responses to prostheses wear particles and released ions are important
13 contributors to hip implant failure. In implant-related adverse reactions T-lymphocytes play a
14 prominent role in sustaining the chronic inflammatory response. To further understand the
15 involvement of lymphocytes in metal-on-metal (MoM) implant failure, primary human
16 lymphocytes were isolated and treated with CoCr wear debris and Co ions, individually, and
17 in combination, for 24, 48, and 120h. There was a significant increase in cell number where
18 debris was present, as measured by the Neutral Red assay. Interleukin 6 (IL-6), interferon γ
19 (IFN γ), and tumour necrosis factor α (TNF α) secretion levels significantly decreased in the
20 presence of metal particles, as measured by ELISA. Interleukin 2 (IL-2) secretion levels were
21 significantly decreased by both debris and Co ions. Flow cytometry analysis showed that the
22 metal nanoparticles induced a significant increase in apoptosis after 48h exposure. This
23 investigation showed that prolonged exposure (120h) to metal debris induces lymphocyte
24 proliferation, suggesting that activation of resting lymphocytes may have occurred. Although
25 cytokine production was affected mainly by metal debris, cobalt toxicity may also modulate
26 IL-2 secretion, and even Co ion concentrations below the MHRA guideline levels (7ppb) may
27 contribute to the impairment of immune regulation *in vivo* in patients with MoM implants.

28
29 **Short abstract**

30 In implant-related adverse reactions T-lymphocytes play a prominent role in sustaining the
31 chronic inflammatory response. Primary human lymphocytes were isolated and treated with
32 CoCr wear debris and Co ions, individually, and in combination, for 24, 48, and 120h.
33 Prolonged exposure to metal debris induced lymphocyte proliferation, suggesting that
34 activation of resting lymphocytes may have occurred. Furthermore, cobalt toxicity may
35 modulate IL-2 secretion, which may contribute to the impairment of immune regulation *in*
36 *vivo* in patients with MoM implants.

37
38 **Key words:** nanoparticles; metal wear debris; metal-on-metal hip replacement; implant
39 failure.

40
41 **Corresponding Author details:** Olga M Posada; Leeds Institute of Cardiovascular and
42 Metabolic Medicine (LICAMM), University of Leeds, LIGHT laboratories, Leeds LS2 9JT,
43 UK; medomp@leeds.ac.uk; TEL: +44 (0) 113 343 7747.

44
45 **Introduction**

46 Modern day metal-on-metal (MoM) total hip resurfacings were introduced in the 1990s
47 (Quesada *et al.*, 2008). They represented approximately 10% of all hip arthroplasties in
48 developed countries between 1990 and 2010 (Corten and MacDonald, 2010; Jiang *et al.*,

¹Current address: LIGHT laboratories, University of Leeds, Leeds LS2 9JT, UK.

49 2011). MoM hip resurfacing bearings are made from high-carbon CoCr alloy (Amstutz and
50 Le Duff, 2006; Mahendra *et al.*, 2009) .

51
52 The most common cause of failure of total hip arthroplasty is aseptic loosening of the implant
53 due predominantly to adverse tissue responses to prostheses wear particles (Luo *et al.*, 2005).
54 Host response to a prosthesis or prosthetic debris results in the formation of a fibrous
55 synovial-like membrane surrounding the prosthesis (Wang *et al.*, 1996). It is believed that
56 mononuclear phagocytic cells in the pseudomembrane surrounding the implant phagocytose
57 wear particles and become activated. This activation results in the release of pro-
58 inflammatory cytokines, such as IL-6 and TNF- α , and inflammatory mediators, such as
59 PGE₂, which stimulate osteoclastic bone resorption (Ingham *et al.*, 2000). Lymphocytes are
60 known to be important regulators of macrophage function (Arora *et al.*, 2003). T cells are
61 recognised as modulators of immune response pathways as a result of stimulation of either
62 the Th1 or Th2 pathway, which involves cell types and cytokines that may influence
63 loosening of total hip replacements (Cachinho *et al.*, 2013). The Th1-cell response is crucial
64 to the activation of macrophages and cytotoxic T-lymphocytes and is involved in the cell-
65 mediated immune response. On the other hand, the Th2-cell response is the most effective
66 activator of B-lymphocytes and is associated with humoral immunity (Cachinho *et al.*, 2013).

67
68 T lymphocytes also play a prominent role in cell mediated type IV hypersensitivity reactions
69 sustaining the chronic inflammatory response. Cell-mediated type-IV hypersensitivity
70 reactions are characterised in vivo by vasculitis with perivascular and intramural lymphocytic
71 infiltration of the postcapillary venules, swelling of the vascular endothelium, recurrent
72 localised bleeding, and necrosis which has been reported following MoM hip replacements
73 (Willert *et al.*, 2005). Lymphocyte infiltrates have also been reported in soft-tissue masses,
74 described as pseudo-tumours, following MoM resurfacing arthroplasty (Boardman *et al.*,
75 2006; Pandit *et al.*, 2008).

76
77 Metals modulate the activities of immunocompetent cells by a variety of mechanisms. The
78 outcome of this modulation depends on the particular metal, its concentration and biological
79 availability (Lawrence and McCabe, 2002). A variety of soluble metals, including Co²⁺ and
80 Cr³⁺, at a range of concentrations between 0.05 and 5mM were found to induce Jurkat T-
81 lymphocyte DNA damage, apoptosis, and/or direct necrosis in a metal-, and concentration-
82 dependent manner (Caicedo *et al.*, 2008).

83
84 Co corrodes faster than Cr under physiological conditions (Xia *et al.*, 2011) and, contrary to
85 Cr, Co ions tend to remain mobile, which is reflected in the higher levels measured in blood,
86 allowing them to reach remote organs (Afolaranmi *et al.*, 2012). Data from the seventh
87 annual report of the National Joint Registry for England and Wales showed high failure rates
88 for MoM hip prostheses, which led to the market recall of the DePuy ASRTM, both the
89 Resurfacing and XL Systems in August 2010 (DePuy International Ltd, Leeds, UK)
90 (MDA/2010/069). Following this, the Medicines and Healthcare products Regulatory Agency
91 (MHRA) safety alert in September 2010 drew attention to the long term biological safety of
92 all types of MoM hip implants. The MHRA have suggested that combined whole blood Co
93 and Cr levels of greater than 7ppb (7 μ g/l or 0.1 μ M) are associated with significant soft-tissue
94 reactions and failed MoM hips (MDA/2010/069). However, there is still considerable debate
95 about the existence of a safe threshold.

96
97 In the present study, the effects of CoCr alloy wear debris and Co ions on primary human
98 lymphocytes were explored in terms of viability, proliferation, cytokine production, and

99 apoptosis. Release of Co and Cr ions from the CoCr debris was measured at physiological pH
100 of 7.4, and at the pH estimated to exist in inflammatory conditions (Mansson *et al.*, 1990).
101 Cells were pretreated with Co ions before exposure to the CoCr wear debris in order to detect
102 any interactions between the ions and particle effects.

103

104 **Methods**

105 *Preparation of wear debris*

106 Co-Cr wear debris was donated by DePuy International (Leeds, UK). A high-carbon cast (\geq
107 0.2%) cobalt chrome (ISO 5832-12: Co Balance, Cr 26.0–30.0%, Mo 5.0–7.0%, Ni 1.0%
108 max., Si 1.0% max., Mn 1.0% max., Fe 0.75% max., C 0.35% max., N 0.25% max.
109 (Dearnley, 1999) hip resurfacing implant was worn on a multi-station hip joint simulator
110 using a non-standard protocol (personal communication, Dr C. Hardaker, DePuy
111 International, Leeds, UK). The wear debris was produced over 250000 cycles using distilled
112 water as the lubricating fluid. Wear debris produced by hip simulator under different
113 conditions has previously been shown to be of similar size and morphology to wear debris
114 produced *in vivo* (Brown *et al.*, 2007). Once produced, the wear debris was centrifuged at
115 3500g for 20 minutes. The debris was heat-treated (180°C for 5h, 60kPa) in a vacuum oven
116 to destroy any endotoxin. The dry debris was then suspended in sterile phosphate buffered
117 saline (PBS; Invitrogen; Paisley, UK). Heat-treated wear debris was characterised with a
118 Field Emission Scanning Electron Microscope (FE-SEM) (Hitachi SU-6600, Hitachi;
119 Germany) at magnifications of 100-1000x. The sample was then transferred to a Scanning
120 Electron Microscope (SEM) (Hitachi TM-1000, Hitachi; Germany). Energy Dispersive X-ray
121 Spectroscopy (EDS) was used for quantitative analysis of elemental composition. Hitachi
122 TM-1000 and EDSwift-TM software was used to obtain the images and chemical spectra of
123 the wear debris. The sterility of the treated wear debris was tested as described elsewhere
124 (Akbar *et al.*, 2012) by exposing dendritic cells (isolated from bone marrow of male BALB/c
125 (Harlan, UK) mouse femurs and tibias (Lutz *et al.*, 1999) to the debris for 24h, *in vitro*, and
126 then assessing the expression of surface activation markers by flow cytometry. The debris
127 was found not to increase the surface expression of CD40, CD86, or MHC II on these cells,
128 and, therefore, the suspended debris was deemed sterile and endotoxin-free (data not shown).

129

130 *ICP-MS analysis of metal ion release from CoCr nanoparticles*

131 Experiments were carried out to determine the extent of metal ion release when wear debris
132 was incubated with cultured cells *in vitro*. In order to assess the effects of foetal calf serum
133 (FCS) and pH on the metal ion release, 2.5mg metal wear debris / 1×10^6 cells were incubated
134 for 24h in RPMI-1640 medium in the presence and absence of FCS and complete RPMI-1640
135 medium, pH 4. Controls of each condition with no metal debris were also present. Standards
136 were prepared by diluting Multielement Standard Solution 1 for ICP (Sigma-Aldrich (Fluka);
137 Dorset, UK) in RPMI-1640. Samples were analysed using an Agilent 7700x octopole
138 collision system ICP-MS (Agilent Technologies; Wokingham, UK) in helium gas mode using
139 scandium as internal standard.

140

141 *Human lymphocyte isolation*

142 Human buffy coat samples were collected from the Scottish Blood Transfusion Service
143 (SNBTS), Glasgow, UK) with ethical permission from the SNBTS Committee for the
144 Governance of Blood and Tissue Samples for Non-Therapeutic Use. All samples had been
145 donated by anonymous healthy donors no more than 5h before use. Peripheral blood
146 mononuclear cells (PBMCs) were isolated under sterile conditions from 60 ml of Buffy Coat
147 by density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich, Cambridge, UK),

148 and lymphocyte enrichment performed as previously described (Martin-Romero *et al.*,
149 2000). Briefly, PBMC (2.5×10^6 cells/ml) were incubated in a 75cm^2 culture flask (TPP,
150 Trasadingen, Switzerland) with complete RPMI-1640 for 1h at 37°C in a 5% (v/v) CO_2
151 chamber. The medium with the non-adherent cell suspension was then transferred to another
152 culture flask and incubated for an additional 1h to further deplete the numbers of any
153 monocytes present in the population. Lymphocyte viability $\geq 90\%$ and a mean lymphocyte
154 yield of 5.89×10^6 cells/ml (± 0.61 SEM, $n=3$) was obtained.

155

156 *Exposure of lymphocytes to wear debris and metal ions*

157 Isolated peripheral human lymphocytes were exposed to metal wear debris and Co^{2+} in a
158 resting state. Lymphocytes were cultured (1×10^5 cells/well) in 96-well round-bottom plates
159 ($100\mu\text{l}$ /well) with 5mg wear debris/ 1×10^6 cells, $0.1\mu\text{M}$ of Co^{2+} and 5mg wear
160 debris/ 1×10^6 cells combined with $0.1\mu\text{M}$ of Co^{2+} in complete RPMI-1640. Cultures were
161 carried out for 24, 48, and 120h at 37°C under 5% (v/v) CO_2 air. For apoptosis analyses,
162 debris concentration was 2.5mg wear debris/ 1×10^6 cells, a lower concentration than for
163 cytotoxicity studies, in order to facilitate detection of early apoptosis.

164

165 *Measurement of viability, proliferation and apoptosis*

166 At 24 and 120h, cell viability was assessed by the neutral red (NR) and MTT assays as
167 described previously (Akbar *et al.*, 2011). Proliferation was determined after 48 and 120h of
168 exposure to the treatments using a BrdU Cell Proliferation Immunoassay kit (kit number
169 QIA58, Merck Chemicals; Nottingham, UK), as suggested by the manufacturer. The
170 absorbance was measured using a Thermo Scientific Multiskan Ascent spectrophotometer
171 plate reader (Thermo Scientific; Hampshire, UK) at dual wavelengths of 450–540nm. At 24
172 and 48h post treatment, lymphocytes cells were collected by centrifugation and incubated for
173 15min with phycoerythrin-labelled annexin V and 7-aminoactinomycin D in the dark. The
174 samples were analysed by a FACSCanto flow cytometer (BD Bioscience, Oxford, UK), and
175 all data were analysed using FACSDiva software.

176

177 *Cytokine secretion measured by ELISA*

178 Cytokine levels were determined by collecting the supernatants from cell cultures at 24 and
179 120h following exposure to the treatments. The concentrations of tumor necrosis factor-alpha
180 ($\text{TNF-}\alpha$), interferon- γ ($\text{IFN}\gamma$), interleukin-2 (IL-2), and interleukin-6 (IL-6) in the culture
181 media were determined from aliquots of cell-free isolates using Ready-Set-Go! ELISA kits
182 (eBioscience; Hatfield, UK) in accordance with the manufacturer's instructions. Each of the
183 kits had a sensitivity level of 4pg/ml, and linear standard curves were generated between 0-
184 500pg/ml for $\text{TNF}\alpha$ and $\text{IFN}\gamma$, 0-250pg/ml for IL-2, and 0-200pg/ml for IL-6. The presence
185 of high concentrations of metal ions did not interfere with detection of cytokines.

186

187 *Statistics*

188 Statistical analyses were carried out by a one-way analysis of variance (ANOVA), followed
189 by a Dunnett's multiple comparison test. Significance was assigned where p values were
190 found to be < 0.05 .

191

192 **Results**

193 The aim of this study was to assess the toxicity of CoCr nanoparticles released from a
194 resurfacing hip implant and Co ions on primary human lymphocytes. In order to achieve this,
195 viability, proliferation, cytokine production, and apoptosis were evaluated in lymphocytes
196 exposed to the ions and the CoCr wear debris particles.

197

198 *Characterisation of heat treated wear debris*

199 SEM images show irregular shapes and sizes varying from the nano to the micro scale (from
200 150nm to 6.5µm). The larger irregular shaped particles suggest that the debris aggregates
201 (Image 1), and this has been reported previously by Akbar and coworkers (2012). Doorn et
202 al(1998) isolated particles from MoM retrieval tissues that varied in size (51-116nm particles
203 to micrometre sized aggregates) and shape. Moreover, metal particles (0.1-3 microns in size)
204 have also been found in tissues post-mortem (Brown *et al.*, 2013). EDS analysis indicated
205 that the wear debris is primarily composed of Co and Cr, which is in agreement with the alloy
206 composition (Singh and Dahotre, 2007). Analysis of 25 different particles indicated a mean
207 composition of 59.57% ($\pm 1.15\%$) Co and 40.43% ($\pm 1.25\%$) Cr, with a small content of Mo
208 which was below the quantification limit.

209

210 *Metal ion release into cell culture medium*

211 Metal debris was incubated, in the absence of cells, under different conditions. Analysis of
212 ICP-MS results found that CoCr wear debris releases metal ions into culture medium (Figure
213 1) was no significant difference ($p > 0.05$) in ion release from metal debris in the presence and
214 absence of 10% (v/v) FCS. This concentration of FCS was used as it was the concentration
215 used when the Co-Cr wear debris was incubated with cells for up to 120h. In contrast to these
216 data, the acidic pH 4.0 had a considerable effect as seen in the significant increase ($p < 0.05$) in
217 the levels of ion release compared with release in medium at normal physiological pH of 7.4.
218 Even though Co was the ion predominantly released in all cases, the change in pH seemed to
219 have a more pronounced effect on Cr ion release.

220

221 *Effects of metal debris and ions on human primary lymphocyte cell viability, proliferation*
222 *and apoptosis.*

223 The viability of primary human lymphocytes was tested after 24 and 120h of exposure to
224 5mg wear debris/ 1×10^6 cells; 0.1µM of Co^{2+} ; and 5mg wear debris/ 1×10^6 cells combined with
225 0.1µM of Co^{2+} . In this study, the 5mg/ 1×10^6 cells debris concentration was chosen to mimic
226 the local metallosis environment surrounding an implant. There was a significant increase in
227 cell number as indicated by the NR assay, measured both at 24 and 120h in the presence of
228 metal debris when compared to controls (Figure 2). Although there was an initial increase in
229 cell number (24h), there was no significant difference in the reduction of MTT in cells in the
230 presence of metal wear debris. Co ions on their own did not seem to have an effect on cell
231 number or cell metabolic activity. These findings suggest that the effects of the debris on the
232 lymphocytes are due to the synergistic action of the nanoparticles and the Co and Cr ions
233 released from the particles.

234

235 Effects on cell proliferation were assessed with the BrdU cell proliferation assay after 48 and
236 120h of treatment with 5mg wear debris/ 1×10^6 cells; 0.1µM of Co^{2+} ; and 5mg wear
237 debris/ 1×10^6 cells combined with 0.1µM of Co^{2+} . At 48h, there is an initial decrease in cell
238 proliferation followed by an increase by 120h of treatment (Figure 3). These results suggest
239 an activation response of the cells to both debris and ions, where the cells overcome the
240 initial growth arrest effect.

241

242 To determine the effects of metal ions on cell damage leading to apoptosis, flow cytometry
243 following Annexin V and 7-AAD staining at 24 and 48h of exposure was performed. To
244 avoid cytotoxic effects and the growth arrest effect observed after exposure to 5mg, a lower
245 debris concentration (2.5mg metal debris/ 1×10^6 cells) was used for apoptosis analysis in
246 order to facilitate the detection of the process at early stages (to measure both early apoptosis
247 and detect any repair). Apoptosis was not observed within 24h of exposure, but was evident

248 after 48h (Figure 5) where the debris caused apoptosis whereas the Co ions did not, and the
249 effect of the debris was unaltered by preincubation with Co ions.

250

251 *Effects of metal debris and ions on cytokine release by human primary lymphocyte cells*

252 Interleukins such as IL-2, IL-6, IFN γ , and TNF α are regarded as indicators of the
253 inflammation evoked by particulate metals (Cachinho *et al.*, 2013). Levels of these four
254 cytokines were determined in the supernatants of human primary lymphocyte cultures after
255 24 and 120h of treatment with cobalt ions and wear debris. There was a general decrease in
256 cytokine production particularly when cells were in contact with metal particles (Figure 4).
257 IFN γ and IL-6 levels decreased after 24h of exposure and continued to be low for 120h.
258 TNF α levels were mainly decreased after 120h of exposure. Interestingly, IL-2 was the only
259 cytokine to be affected by all treatments. Cobalt ion treatment did not have an effect on IL-6,
260 IFN γ , and TNF α production.

261

262

263 **Discussion**

264 Several studies have described accumulation of perivascular lymphocytes in tissue
265 membranes around failed MoM implants apparently not associated with infection, and these
266 authors have interpreted this inflammation as an immunologic reaction against metal ions or
267 metal particles associated with those articulations (Bohler *et al.*, 2002; Davies *et al.*, 2005;
268 Willert *et al.*, 2005; Korovessis *et al.*, 2006; Campbell *et al.*, 2010). In the present study,
269 primary human lymphocytes were exposed to Co ions and high concentrations of metal wear
270 debris derived from a MoM hip resurfacing device in order to evaluate the cell response to
271 these treatments and to assess whether or not CoCr particles and ions could activate primary
272 cultures of human lymphocytes.

273

274 The wear debris used in this study was produced from a 39mm ASRTM prosthesis, and
275 previous work replicating natural gait on a simulator has shown that approximately 8 mm³ of
276 debris is produced per million cycles from this prosthesis (Leslie *et al.*, 2008). The density of
277 the CoCr alloy used was 8.32mg/mm³ (Medley *et al.*, 1996), so 66.56mg debris would be
278 produced per million cycles. An active person might walk 3.5 million cycles per year, so
279 232.96mg debris/year would be produced locally in the environment of the prosthesis. The
280 5mg/1x10⁶cells metal debris concentration used in this investigation was chosen to mimic
281 metallosis, a situation where metallic debris infiltrates into the periprosthetic tissues, with
282 resulting severe adverse effects. The range of debris and ion concentrations measured locally
283 varies hugely in the literature, for example, in catastrophic failure of a prosthesis amounts of
284 wear debris up to 67mg have been reported (Matziolis *et al.*, 2003).

285

286 Cellular uptake of the wear debris by the lymphocytes was not demonstrated in the present
287 study primarily due to technical difficulties in proving uptake by SEM. Showing specific
288 uptake of the CoCr debris would have made a significant contribution to the study. However,
289 uptake of dextran coated glass beads of similar size range was measured by fluorescent
290 labelling proving that the lymphocytes were capable of phagocytosis.

291

292 T-lymphocytes are normally maintained in a quiescent state while remaining capable of rapid
293 responses and effector function (Macintyre and Rathmell). T-cell proliferation occurs as the
294 result of a precisely orchestrated set of events involving two distinct signals, namely
295 recognition of an antigen followed by release of co-stimulatory molecules such as IL-2
296 cytokine (Deweck *et al.*, 1984; Habetswallner *et al.*, 1988). After activation, T cells undergo
297 a transient period with little cell growth and then begin to rapidly grow and divide (Macintyre

298 and Rathmell). In this investigation, high concentrations of metal debris caused an increase in
299 cell number despite the initial decrease in cell proliferation suggesting that the particles may
300 exert a cell activation effect. It is proposed that this took place during the first 48h of
301 treatment reflected by the initial lower proliferation rates (24-48h) followed by the rapid
302 growth and division seen by 120h. In addition to this, a significant decrease in IL-2
303 production was observed after 24h of exposure to all the treatments. Since IL-2 is an
304 important molecule for lymphocyte activation and proliferation, its diminished production
305 could have contributed to the decrease in proliferation observed at 48h.

306
307 A state of reduced function in which a viable, antigen-specific T cell is unable to respond to
308 an immunogenic stimulus has been referred to as anergy (Zheng *et al.*, 2008). Anergy can be
309 induced under a number of circumstances that can be categorised as resulting from either a
310 normal antigenic stimulus received in the absence of co-stimulation or from an altered and/or
311 chronic T-cell receptor stimulus (Wells, 2009). To the authors' knowledge, anergy has not
312 been described as part of the biological reaction to metal debris and ions, and most studies
313 report implant-related hypersensitivity reactions, in particular type-IV delayed-type
314 hypersensitivity mediated by T lymphocytes. Nevertheless, results from this investigation
315 suggest that there may be an anergy-like response to high concentrations of metal debris. The
316 significant decrease in IL-2 production and proliferation observed here are hallmarks of T-
317 cell anergy (Chappert and Schwartz, 2010; Kuklina, 2013). Moreover, defective production
318 of inflammatory cytokines such as IFN γ and TNF α is also a characteristic of anergy (Wells,
319 2009) and significant decreases in both cytokines were observed in the present study in the
320 presence of metal debris.

321
322 Metals corrode *in vivo* releasing metal ions (Hanawa, 2004). Such ions can potentially bind to
323 proteins, remain in solution, or disseminate into the surrounding tissues and bloodstream, and
324 thus reach remote organs. The microenvironment conditions surrounding the debris can
325 influence the rate of ion release (Cadosch *et al.*, 2009). It is generally presumed that metal
326 ions facilitate cell activation and sensitization. However, depending on the concentration of
327 metal ions present, they may also be cytotoxic and suppressive. It has been shown that
328 production of TNF α and IL-6 by human peripheral blood mononuclear cells exposed to Cr (1,
329 5, and 10 μ M) significantly decreases (Villanueva *et al.*, 2000). In the current investigation,
330 inhibition of cytokine production was observed in the presence of metal particles. IFN γ ,
331 TNF α , and IL-6 levels did not seem to be affected by Co ions alone, whereas IL-2 levels were
332 decreased. Although the effects of Cr may be related to the regulation of TNF α and IL-6, IL-
333 2 production is more likely to be modulated by Co. Additionally, high concentrations (5mg
334 debris/1x10⁶cells) of metal debris were not cytotoxic to primary lymphocytes. However, a
335 marked increase in apoptosis was observed at a lower dose (2.5mg debris/1x10⁶cells). These
336 findings suggest a dose dependent effect on cell damage pathways. Akbar *et al.* (2011)
337 exposed resting and activated lymphocytes to a range of Co and Cr ions. They found that
338 exposure to higher concentrations of Cr⁶⁺ (10 and 100 μ M), and Co²⁺ (100 μ M) significantly
339 decreased cell viability and increased apoptosis in both resting and activated lymphocytes at
340 24 and 48h of exposure. In their study metal ions were assessed independently. The effects
341 observed in the current study are the results of the concerted action of the particles and both
342 Co and Cr ions. It would have been interesting to pre-incubate the cells with Co ions and
343 subsequently treat them with the particles to identify if sensitisation occurs. In fact, priming
344 human monocyte-like U937 cells with Co ions for subsequent challenge with wear debris has
345 been investigated in our laboratory (Posada *et al.*, 2014). Results from such investigation
346 showed that metal debris was more effective as an inducer of apoptosis and gene expression
347 when cells had been pre-treated with Co ions. However, this set of experiments could not

348 readily be performed with the primary lymphocytes due to difficulties in maintaining
349 prolonged culture.

350

351 Released metal ions can activate the immune system by forming metal-protein complexes
352 that are considered to be candidate antigens for eliciting hypersensitivity responses
353 (Korovessis *et al.*, 2006). Upon recognition by lymphocytes, the metal-protein complexes
354 induce the production of proinflammatory cytokines and chemokines by various cell types
355 due to triggering of innate immune responses (Martin, 2004). According to this, it is thought
356 that high local metal ion and nanoparticles concentrations facilitate a T-lymphocyte mediated
357 inflammatory response resulting in the destruction seen around the prostheses (Davies *et al.*,
358 2005; Willert *et al.*, 2005; Boardman *et al.*, 2006; Kwon *et al.*, 2010). Three mechanisms
359 have been proposed by which metal-protein complexes can activate lymphocytes: 1. antigen-
360 independent, 2. antigen-dependent, and 3. superantigen-like, which is a synergistic
361 combination of the first two mechanisms (Hallab *et al.*, 2001b). Metals may act with serum
362 proteins to crosslink lymphocyte receptors (e.g., BV17 of CDR1 T cell receptor) without the
363 presence of an antigen-presenting cell leading to a superantigen enhancement of T cell
364 receptor-protein contact (Vollmer *et al.*, 1997; Vollmer *et al.*, 1999). In this circumstance,
365 proteins or peptides that would not otherwise be antigenic are able to provoke a response
366 (Hallab *et al.*, 2001b). The lymphocyte reactions in the current investigation seem to be
367 consistent with such nonspecific mitogenic activation mechanisms, which could explain the
368 increase in cell proliferation despite the significant decrease in IL-2 production.

369

370 Implant failure is largely caused by aseptic loosening and osteolysis (Huber *et al.*, 2010) in
371 response to accumulation of metal particles in the periprosthetic tissues, which also generates
372 inflammation, pain, and pseudotumours (Langton *et al.*, 2011). Evidence of systemic effects
373 can also be found in multiple reports (Steens *et al.*, 2006; Oldenburg *et al.*, 2009; Rizzetti *et*
374 *al.*, 2009; Ikeda *et al.*, 2010; Tower, 2010; Machado *et al.*, 2012; Pelclova *et al.*, 2012;
375 Tower, 2012) describing patients with MoM implants who presented symptoms including
376 neurological symptoms such as auditory impairment/deafness, visual impairment/blindness,
377 peripheral neuropathy/dysesthesia of the extremities, poor concentration/cognitive decline,
378 cardiomyopathy and hypothyroidism. All patients had elevated cobalt and/or chromium
379 concentrations in their blood, serum, plasma, and/or urine, suggesting that these systemic
380 symptoms may be due to metal toxicity as a result of excessive implant wear. Polyzois *et al*
381 (2012), reviewed the evidence of local and systemic toxicity of wear debris from total hip
382 arthroplasty. They found extensive evidence and experimental data supporting the fact that
383 orthopaedic metals induce local immunological effects characterised by an unusual
384 lymphocytic infiltration and cell-mediated hypersensitivity. In terms of systemic toxicity,
385 there are *in vivo* and *in vitro* experimental, as well as a limited number of epidemiological
386 studies, where the systems most commonly involved are haematopoietic, immune,
387 hepatobiliary, renal, respiratory, nervous, cardiovascular, musculoskeletal, skin, and
388 endocrine and reproductive. Concern has been raised regarding a potential link between
389 metal wear debris and carcinogenesis. In an attempt to address this, Christian *et al* (2014)
390 used quantitative methods to evaluate the relationship between CoCr-containing hip implants
391 and increased cancer risk. They concluded that although the evidence suggests that such
392 implants are unlikely to be associated with an increased risk of systemic cancers, additional
393 research is warranted in this area.

394

395 The importance of Co ions in the inflammatory responses to CoCr particles has been
396 recognised, and chronic exposure to circulating levels of ions, plus high local concentrations
397 may act synergistically *in vivo* to trigger and promote implant loosening (Hallab *et al.*, 2001a;

398 Caicedo *et al.*, 2010; Hart *et al.*, 2012). The present study has shown that high concentrations
399 of wear debris, derived from a CoCr MoM hip resurfacing, induce lymphocyte proliferation
400 and inhibit cytokine production after 120h exposure. The fact that IL-2 production was
401 affected by 0.1µM Co (5.9ppb or 5.9µg/L) suggests that even circulating blood metal ion
402 concentrations within the MHRA guideline levels of 7ppb or 7µg/L (MHRA) may contribute
403 to the impairment of immune regulation in patients with MoM implants.

404

405 **Acknowledgements**

406 This study was supported by an Overseas Research Studentship awarded to Olga M. Posada,
407 and by funds from University of Strathclyde. The authors are grateful to Dr C Hardaker
408 (DePuy International) who prepared the CoCr nanoparticles.

409

410 **References**

411 Afolaranmi, G.A., Akbar, M., Brewer, J., Grant, M.H., 2012. Distribution of metal released
412 from cobalt-chromium alloy orthopaedic wear particles implanted into air pouches in mice. *J*
413 *Biomed Mater Res A*. **100A**, 1529-1538. doi: 10.1002/jbm.a.34091.

414 Akbar, M., Brewer, J.M., Grant, M.H., 2011. Effect of chromium and cobalt ions on primary
415 human lymphocytes in vitro. *J Immunotoxicol.* **8**, 140-149. doi:
416 10.3109/1547691X.2011.553845.

417 Akbar, M., Fraser, A.R., Graham, G.J., Brewer, J.M., Grant, M.H., 2012. Acute inflammatory
418 response to cobalt chromium orthopaedic wear debris in a rodent air-pouch model. *J R Soc*
419 *Interface*. **9**, 2109-2119. doi: 10.1098/rsif.2012.0006.

420 Amstutz, H.C., Le Duff, M.J., 2006. Background of metal-on-metal resurfacing. *Proc Inst*
421 *Mech Eng H*. **220**, 85-94.

422 Arora, A., Song, Y., Chun, L., Huie, P., Trindade, M., Smith, R.L., Goodman, S., 2003. The
423 role of the TH1 and TH2 immune responses in loosening and osteolysis of cemented total hip
424 replacements. *J Biomed Mater Res A*. **64A**, 693-697.

425 Boardman, D.R., Middleton, F.R., Kavanagh, T.G., 2006. A benign psoas mass following
426 metal-on-metal resurfacing of the hip. *J Bone Joint Surg Br*. Volume **88B**, 402-404.

427 Bohler, M., Kanz, F., Schwarz, B., Steffan, I., Walter, A., Plenck, H., Knahr, K., 2002.
428 Adverse tissue reactions to wear particles from Co-alloy articulations, increased by alumina-
429 blasting particle contamination from cementless Ti-based total hip implants - A report of
430 seven revisions with early failure. *J Bone Joint Surg Br*. Volume **84B**, 128-136.

431 Brown, C., Lacharme-Lora, L., Mukonoweshuro, B., Sood, A., Newson, R.B., Fisher, J.,
432 Case, C.P., Ingham, E., 2013. Consequences of exposure to peri-articular injections of micro-
433 and nano-particulate cobalt-Chromium alloy. *Biomaterials* **34**, 8564-8580. doi:
434 10.1016/j.biomaterials.2013.07.073.

435 Brown, C., Williams, S., Tipper, J.L., Fisher, J., Ingham, E., 2007. Characterisation of wear
436 particles produced by metal on metal and ceramic on metal hip prostheses under standard and
437 microseparation simulation. *J Mater Sci Mater Med*. **18**, 819-827.

438 Cachinho, S.C.P., Pu, F.R., Hunt, J.A., 2013. Cytokine secretion from human peripheral
439 blood mononuclear cells cultured in vitro with metal particles. *J Biomed Mater Res A*. **101A**,
440 1201-1209. doi: 10.1002/jbm.a.34410.

441 Cadosch, D., Chan, E., Gautschi, O.P., Filgueira, L., 2009. Metal is not inert: Role of metal
442 ions released by biocorrosion in aseptic loosening-Current concepts. *J Biomed Mater Res A*.
443 **91A**, 1252-1262. doi: 10.1002/jbm.a.32625

444 Caicedo, M., Jacobs, J.J., Reddy, A., Hallab, N.J., 2008. Analysis of metal ion-induced DNA
445 damage, apoptosis, and necrosis in human (Jurkat) T-cells demonstrates Ni²⁺, and V³⁺ are
446 more toxic than other metals: Al³⁺, Be²⁺, Co²⁺, Cr³⁺, Cu²⁺, Fe³⁺, Mo⁵⁺, Nb⁵⁺, Zr²⁺. *J Biomed*
447 *Mater Res A*. **86A**, 905-913.

448 Caicedo, M.S., Pennekamp, P.H., McAllister, K., Jacobs, J.J., Hallab, N.J., 2010. Soluble
449 ions more than particulate cobalt-alloy implant debris induce monocyte costimulatory
450 molecule expression and release of proinflammatory cytokines critical to metal-induced
451 lymphocyte reactivity. *J Biomed Mater Res A*. **93A**, 1312-1321. doi: 10.1002/jbm.a.32627
452 Campbell, P., Ebramzadeh, E., Nelson, S., Takamura, K., De Smet, K., Amstutz, H.C., 2010.
453 Histological Features of Pseudotumor-like Tissues From Metal-on-Metal Hips. *Clin Orthop*
454 *Relat Res*. **468**, 2321-2327. doi: 10.1007/s11999-010-1372-y.
455 Chappert, P., Schwartz, R.H., 2010. Induction of T cell anergy: integration of environmental
456 cues and infectious tolerance. *Curr Opin Immunol*. **22**, 552-559. doi:
457 10.1016/j.coi.2010.08.005.
458 Christian, W.V., Oliver, L.D., Paustenbach, D.J., Kreider, M.L., Finley, B.L., 2014.
459 Toxicology-based cancer causation analysis of CoCr-containing hip implants: a quantitative
460 assessment of genotoxicity and tumorigenicity studies. *J Appl Toxicol*. **34**, 939-967. doi:
461 10.1002/jat.3039.
462 Corten, K., MacDonald, S.J., 2010. Hip resurfacing data from national joint registries What
463 do they tell us? What do they not tell us? *Clin Orthop Relat Res*. **468**, 351-357. doi:
464 10.1007/s11999-009-1157-3.
465 Davies, A.P., Willert, H.G., Campbell, P.A., Learmonth, I.D., Case, C.P., 2005. An unusual
466 lymphocytic perivascular infiltration in tissues around contemporary metal-on-metal joint
467 replacements. *J Bone Joint Surg Am*. Volume **87A**, 18-27.
468 Dearnley, P.A., 1999. A review of metallic, ceramic and surface-treated metals used for
469 bearing surfaces in human joint replacements. *Proc Inst Mech Eng H*. **213**, 107-135.
470 Deweck, A.L., Kristensen, F., Joncourt, F., Bettens, F., Walker, C., Wang, Y., 1984. Analysis
471 of lymphocyte-proliferation by cytofluorometric techniques in aging and various clinical
472 conditions. *Asian Pac J Allergy Immunol*. **2**, 253-261.
473 Doorn, P.F., Campbell, P.A., Worrall, J., Benya, P.D., McKellop, H.A., Amstutz, H.C., 1998.
474 Metal wear particle characterization from metal on metal total hip replacements:
475 Transmission electron microscopy study of periprosthetic tissues and isolated particles. *J*
476 *Biomed Mater Res*. **42**, 103-111.
477 Habetswallner, D., Pelosi, E., Bulgarini, D., Camagna, A., Samoggia, P., Montesoro, E.,
478 Giannella, G., Lazzaro, D., Isacchi, G., Testa, U., Peschle, C., 1988. Activation and
479 proliferation of normal resting human lymphocytes-t in serum-free culture - role of IL-4 and
480 IL-6. *Immunology* **65**, 357-364.
481 Hallab, N., Merritt, K., Jacobs, J.J., 2001a. Metal sensitivity in patients with orthopaedic
482 implants. *J Bone Joint Surg Am*. Volume **83A**, 428-436.
483 Hallab, N.J., Mikecz, K., Vermes, C., Skipor, A., Jacobs, J.J., 2001b. Differential lymphocyte
484 reactivity to serum-derived metal-protein complexes produced from cobalt-based and
485 titanium-based implant alloy degradation. *J Biomed Mater Res*. **56**, 427-436.
486 Hanawa, T., 2004. Metal ion release from metal implants. *Mater Sci Eng C Mater Biol Appl*
487 **24**, 745-752. doi: 10.1016/j.msec.2004.08.018.
488 Hart, A.J., Quinn, P.D., Lali, F., Sampson, B., Skinner, J.A., Powell, J.J., Nolan, J., Tucker,
489 K., Donell, S., Flanagan, A., Mosselmanns, J.F.W., 2012. Cobalt from metal-on-metal hip
490 replacements may be the clinically relevant active agent responsible for periprosthetic tissue
491 reactions. *Acta Biomater*. **8**, 3865-3873. doi: 10.1016/j.actbio.2012.05.003.
492 Huber, M., Reinisch, G., Zenz, P., Zweymueller, K., Lintner, F., 2010. Postmortem study of
493 femoral osteolysis associated with metal-on-metal articulation in total hip replacement an
494 analysis of nine cases. *J Bone Joint Surg Am*. Volume **92A**, 1720-1731. doi:
495 10.2106/JBJS.I.00695.

496 Ikeda, T., Takahashi, K., Kabata, T., Sakagoshi, D., Tomita, K., Yamada, M., 2010.
497 Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. *Muscle*
498 *Nerve* **42**, 140-143. doi: 10.1002/mus.21638.

499 Ingham, E., Green, T.R., Stone, M.H., Kowalski, R., Watkins, N., Fisher, J., 2000. Production
500 of TNF-alpha and bone resorbing activity by macrophages in response to different types of
501 bone cement particles. *Biomaterials* **21**, 1005-1013.

502 Jiang, Y., Zhang, K., Die, J., Shi, Z., Zhao, H., Wang, K., 2011. A systematic review of
503 modern metal-on-metal total hip resurfacing vs standard total hip arthroplasty in active young
504 patients. *J Arthroplasty*. **26**, 419-426. doi: 10.1016/j.arth.2010.07.008.

505 Korovessis, P., Petsinis, G., Repanti, M., Repantis, T., 2006. Metallosis after contemporary
506 metal-on-metal total hip arthroplasty - Five to nine-year follow-up. *J Bone Joint Surg Am*
507 Volume **88A**, 1183-1191.

508 Kuklina, E.M., 2013. Molecular mechanisms of T-cell anergy. *Biochemistry (Mosc)*. **78**, 144-
509 156. doi: 10.1134/S000629791302003X.

510 Kwon, Y.M., Glyn-Jones, S., Simpson, D.J., Kamali, A., McLardy-Smith, P., Gill, H.S.,
511 Murray, D.W., 2010. Analysis of wear of retrieved metal-on-metal hip resurfacing implants
512 revised due to pseudotumours. *J Bone Joint Surg Br*. Volume **92B**, 356-361. doi:
513 10.1302/0301-620X.92B3.23281.

514 Langton, D.J., Joyce, T.J., Jameson, S.S., Lord, J., Van Orsouw, M., Holland, J.P., Nargol,
515 A.V.F., De Smet, K.A., 2011. Adverse reaction to metal debris following hip resurfacing.
516 The influence of component type, orientation and volumetric wear. *J Bone Joint Surg Br*.
517 Volume **93B**, 164-171. doi: 10.1302/0301-620X.93B2.25099.

518 Lawrence, D.A., McCabe, M.J., 2002. Immunomodulation by metals. *Int Immunopharmacol*
519 **2**, 293-302.

520 Leslie, I., Williams, S., Brown, C., Isaac, G., Jin, Z., Ingham, E., Fisher, J., 2008. Effect of
521 bearing size on the long-term wear, wear debris, and ion levels of large diameter metal-on-
522 metal hip replacements - An in vitro study. *J J Biomed Mater Res B Appl Biomater*. **87B**,
523 163-172. doi: 10.1002/jbm.b.31087.

524 Luo, L., Petit, A., Antoniou, J., Zukor, D.J., Huk, O.L., Liu, R.C.W., Winnik, F.M., Mwaile,
525 F., 2005. Effect of cobalt and chromium ions on MMP-1 TIMP-1, and TNF-alpha gene
526 expression in human U937 macrophages: A role for tyrosine kinases. *Biomaterials* **26**, 5587-
527 5593.

528 Lutz, M.B., Kukutsch, N., Ogilvie, A.L.J., Rossner, S., Koch, F., Romani, N., Schuler, G.,
529 1999. An advanced culture method for generating large quantities of highly pure dendritic
530 cells from mouse bone marrow. *J Immunol Methods* **223**, 77-92.

531 Machado, C., Appelbe, A., Wood, R., 2012. Arthroprosthetic cobaltism and cardiomyopathy.
532 *Heart Lung Circ*. **21**, 759-760. doi: 10.1016/j.hlc.2012.03.013.

533 Macintyre, A., Rathmell, J., Activated lymphocytes as a metabolic model for carcinogenesis.
534 *Cancer Metab C7 - 5* **1**, 1-12. doi: 10.1186/2049-3002-1-5.

535 Mahendra, G., Pandit, H., Kliskey, K., Murray, D., Gill, H.S., Athanasou, N., 2009. Necrotic
536 and inflammatory changes in metal-on-metal resurfacing hip arthroplasties Relation to
537 implant failure and pseudotumor formation. *Acta Orthop*. **80**, 653-659. doi:
538 10.3109/17453670903473016.

539 Mansson, B., Geborek, P., Saxne, T., Bjornsson, S., 1990. Cytidine deaminase activity in
540 synovial-fluid of patients with rheumatoid-arthritis - Relation to lactoferrin, acidosis, and
541 cartilage proteoglycan release. *Ann Rheum Dis* **49**, 594-597.

542 Martin-Romero, C., Santos-Alvarez, J., Goberna, R., Sanchez-Margalet, V., 2000. Human
543 leptin enhances activation and proliferation of human circulating T lymphocytes. *Cell*
544 *Immunol*. **199**, 15-24.

545 Martin, S.F., 2004. T lymphocyte-mediated immune responses to chemical haptens and metal
546 ions: Implications for allergic and autoimmune disease. *Int Arch Allergy Immunol.* **134**, 186-
547 198.

548 Matziolis, G., Perka, C., Disch, A., 2003. Massive metallosis after revision of a fractured
549 ceramic head onto a metal head. *Arch Orthop Trauma Surg.* **123**, 48-50.

550 Medley, J.B., Chan, F.W., Krygier, J.J., Bobyn, J.D., 1996. Comparison of alloys and designs
551 in a hip simulator study of metal on metal implants. *Clin Orthop Relat Res.*, S148-S159.

552 Oldenburg, M., Wegner, R., Baur, X., 2009. Severe cobalt intoxication due to prosthesis wear
553 in repeated total hip arthroplasty. *J Arthroplasty.* **24**, 825.e815-820. doi:
554 10.1016/j.arth.2008.07.017.

555 Pandit, H., Glyn-Jones, S., McLardy-Smith, P., Gundle, R., Whitwell, D., Gibbons, C.L.M.,
556 Ostlere, S., Athanasou, N., Gill, H.S., Murray, D.W., 2008. Pseudotumours associated with
557 metal-on-metal hip resurfacings. *J Bone Joint Surg Br. Volume* **90B**, 847-851. doi:
558 10.1302/0301-620X.90B7.20213.

559 Pelclova, D., Sklensky, M., Janicek, P., Lach, K., 2012. Severe cobalt intoxication following
560 hip replacement revision: Clinical features and outcome. *Clin Toxicol (Phila).* **50**, 262-265.
561 doi: 10.3109/15563650.2012.670244.

562 Polyzois, I., Nikolopoulos, D., Michos, I., Patsouris, E., Theocharis, S., 2012. Local and
563 systemic toxicity of nanoscale debris particles in total hip arthroplasty. *J Appl Toxicol.* **32**,
564 255-269. doi: 10.1002/jat.2729.

565 Posada, O.M., Gilmour D., Tate R.J., Grant M.H., 2014. CoCr wear particles generated from
566 CoCr alloy metal-on-metal hip replacements, and cobalt ions stimulate apoptosis and
567 expression of general toxicology-related genes in monocyte-like U937 cells. *Toxicol Appl*
568 *Pharmacol.* **281**, 125-135. doi: 10.1016/j.taap.2014.09.010

569 Quesada, M.J., Marker, D.R., Mont, M.A., 2008. Metal-on-metal hip resurfacing. *J*
570 *Arthroplasty.* **23**, 69-73. doi: 10.1016/j.arth.2008.06.015.

571 Rizzetti, M.C., Liberini, P., Zarattini, G., Catalani, S., Pazzaglia, U., Apostoli, P., Padovani,
572 A., 2009. Loss of sight and sound. Could it be the hip? *Lancet* **373**, 1052-1052. doi:
573 10.1016/S0140-6736(09)60490-6.

574 Singh, R., Dahotre, N.B., 2007. Corrosion degradation and prevention by surface
575 modification of biometallic materials. *J Mater Sci Mater Med* **18**, 725-751.

576 Steens, W., von Foerster, G., Katzer, A., 2006. Severe cobalt poisoning with loss of sight
577 after ceramic-metal pairing in a hip- a case report. *Acta Orthop.* **77**, 830-832.

578 Tower, S.S., 2010. Arthroprosthetic cobaltism: neurological and cardiac manifestations in
579 two patients with metal-on-metal arthroplasty. A case report. *J Bone Joint Surg Am. Volume*
580 **92A**, 2847-2851. doi: 10.2106/JBJS.J.00125.

581 Tower, S.S., 2012. Metal on metal hip implants. Arthroprosthetic cobaltism associated with
582 metal on metal hip implants. *BMJ.* 344e430. doi: 10.1136/bmj.e430.

583 Villanueva, M.B.G., Koizumi, S., Jonai, H., 2000. Cytokine production by human peripheral
584 blood mononuclear cells after exposure to heavy metals. *J Health Sci* **46**, 358-362.

585 Vollmer, J., Fritz, M., Dormoy, A., Weltzien, H.U., Moulon, C., 1997. Dominance of the
586 BV17 element in nickel-specific human T cell receptors relates to severity of contact
587 sensitivity. *Eur J Immunol.* **27**, 1865-1874.

588 Vollmer, J., Weltzien, H.U., Moulon, C., 1999. TCR reactivity in human nickel allergy
589 indicates contacts with complementarity-determining region 3 but excludes superantigen-like
590 recognition. *J Immunol.* **163**, 2723-2731.

591 Wang, J.Y., Wicklund, B.H., Gustilo, R.B., Tsukayama, D.T., 1996. Titanium, chromium and
592 cobalt ions modulate the release of bone-associated cytokines by human
593 monocytes/macrophages in vitro. *Biomaterials* **17**, 2233-2240.

594 Wells, A.D., 2009. New insights into the molecular basis of t cell anergy: Anergy factors,
595 avoidance sensors, and epigenetic imprinting. *J Immunol.* **182**, 7331-7341. doi:
596 10.4049/jimmunol.0803917.
597 Willert, H.G., Buchhorn, G.H., Fayyazi, A., Flury, R., Windler, M., Koster, G., Lohmann,
598 C.H., 2005. Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints
599 - A clinical and histomorphological study. *J Bone Joint Surg Am.* Volume **87A**, 28-36.
600 Xia, Z.D., Kwon, Y.M., Mehmood, S., Downing, C., Jurkschat, K., Murray, D.W., 2011.
601 Characterization of metal-wear nanoparticles in pseudotumor following metal-on-metal hip
602 resurfacing. *Nanomedicine* **7**, 674-681. doi: 10.1016/j.nano.2011.08.002.
603 Zheng, Y., Zha, Y.Y., Gajewski, T.F., 2008. Molecular regulation of T-cell anergy. *EMBO*
604 *Rep.* **9**, 50-55. doi: 10.1038/sj.embor.7401138.

605

606 **Web References**

- 607 1. Australian Orthopaedic Association National Joint Replacement Registry, A., 2011. Hip
608 and Knee Arthroplasty Annual Report 2011 [http://www.surfacehippy.info/pdf/australian-nat-](http://www.surfacehippy.info/pdf/australian-nat-reg-2011.pdf)
609 [reg-2011.pdf](http://www.surfacehippy.info/pdf/australian-nat-reg-2011.pdf) [last accessed 13/02/2014].
- 610 2. Canadian Joint Replacement Registry, C., 2013. Title Hip and Knee Replacements in
611 Canada: Canadian Joint Replacement Registry 2013 Annual
612 Report. https://secure.cihi.ca/free_products/CJRR_2013_Annual_Report_EN.pdf [last
613 accessed 13/02/2014].
- 614 3. National Joint Registry, N., 2012. National Joint Registry for England and Wales 9th
615 Annual Report.
616 [http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/9th_annual_rep-](http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/9th_annual_report/NJR%209th%20Annual%20Report%202012.pdf)
617 [ort/NJR%209th%20Annual%20Report%202012.pdf](http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/9th_annual_report/NJR%209th%20Annual%20Report%202012.pdf) [last accessed 13/02/2014].
- 618 4. MDA/2010/069, Medical Device Alert. Ref: MDA/2010/069. Issues: 7 September
619 2010. [http://www.mhra.gov.uk/home/groups/dts-](http://www.mhra.gov.uk/home/groups/dts-bs/documents/medicaldevicealert/con093791.pdf)
620 [bs/documents/medicaldevicealert/con093791.pdf](http://www.mhra.gov.uk/home/groups/dts-bs/documents/medicaldevicealert/con093791.pdf) [last accessed 13/02/2014].
- 621 5. MHRA, Medical Device Alert. Ref: MDA/2010/033. Issues: 22 April 2010.
622 <http://www.dhsspsni.gov.uk/mda-2010-033.pdf> [last accessed 13/02/2014].

623 **Figure and Image legends**

624

625 **Image 1. Scanning Electron Microscopy images of simulator generated wear debris**
626 **from an ASR hip implant.** Image taken at 5000X with a FE-SEM Hitachi SU-6600.

627

628 **Figure 1. Metal ions in RPMI-1640 in the presence and absence of metal wear debris.**
629 Results are expressed as mean values (\pm SEM, n=3). (a) Cr ion concentrations. (b) Co ion
630 concentrations. *Significantly different from control values ($p < 0.05$) by one-way ANOVA
631 followed by Dunnett's multiple comparison test. ^bSignificant difference between pH 7.4 and
632 pH 4.0.

633

634 **Figure 2. Cell number (NR) and metabolic activity (MTT) of human lymphocytes.**
635 Results are expressed as percentages (\pm SEM, n=12) where 100% represents control untreated
636 cells. (a) Effects on cell number as measured by NR. (b) Cell metabolic activity as measured
637 by MTT. *Significantly different from control values ($p < 0.05$) by one-way ANOVA followed
638 by Dunnett's multiple comparison test.

639

640 **Figure 3. Proliferation of human lymphocytes measured by BrdU assay.** Results are
641 expressed as percentages (\pm SEM, n=6) where 100% represents control untreated cells.
642 *Significantly different from control values ($p < 0.05$) by one-way ANOVA followed by
643 Dunnett's multiple comparison test.

644

645 **Figure 4. Cytokine production by human lymphocytes.** Results are expressed as mean
646 values (\pm SEM, n=4). (a) TNF- α levels. (b) INF- γ levels. (c) IL-6 levels. (d) IL-2 levels.
647 *Significantly different from control values ($p < 0.05$) by one-way ANOVA followed by
648 Dunnett's multiple comparison test.

649

650 **Figure 5. Early and late apoptosis.** Results are expressed as percentages (\pm SEM, n=12). (a)
651 Percentage of early apoptosis after 24h of treatment. (b) Percentage of late apoptosis after
652 24h of treatment. (c) Percentage of early apoptosis after 48h of treatment. (d) Percentage of
653 late apoptosis after 48h of treatment. *Significantly different from control values ($p < 0.05$) by
654 one-way ANOVA followed by Dunnett's multiple comparison test.

655




Image 1




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5